北京招聘

• Communicate and coordinate with the study team and applicable external vendors
• Provide operational leadership of data management tasks for assigned studies from start-up to close-out (including but not limited to eCRF design & edit checks, UAT, data management plan, data review & reporting, medical coding, data import/export, transformation to SDTM, database lock).
• Ensure adequate documentation and application of internal and industry standards/best practices across studies.
• Oversee CROs and vendors for all data management related activities, providing consistent team direction/guidance and monitoring quality of work through key performance metrics.
• Represent Data Management at cross-functional team meetings providing accurate study status updates and proactive communication/escalation of data management issues and risks.
• Participate in Data Management department infrastructure, by contributing to SOPs/work instructions development, CRF standards development and cross-functional process improvement initiatives.

任职要求：

• At least 3 years of experience in data management is required and a BA/BS degree is required.
• Extensive technical experience using EDC systems (ideally Medidata RAVE) and MS Office products.
• In-depth knowledge of DM industry standards, best practices and CDISC implementation (CDASH, ODM, SDTM).
• Ability to perform all job functions with minimal to no direct supervision and possess a full understanding of all aspects of data management.
• Excellent written, verbal and organizational skills.
• Good project management skills.
• Good team collaboration.

Location：Shanghai/Suzhou

创胜集团是一家临床阶段的在生物药发现、研发、工艺开发和生产方面具有全面综合能力的生物制药公司。2021年9月29日，创胜集团在香港联合交易所主板上市，股票代码：06628。

创胜集团总部位于苏州，已成功搭建了全球的业务布局：在苏州设有药物发现、临床和转化研究中心，在杭州拥有工艺与产品开发中心以及药物生产基地，在北京、上海、广州和美国普林斯顿分别设有临床开发中心，并在美国波士顿、洛杉矶设立了对外合作中心。创胜集团的开发管线已有九个治疗用抗体新药分子，涵盖肿瘤、骨科和肾病等领域。

迈博斯生物医药(苏州)有限公司是创胜集团医药有限公司的全资附属公司，由国家创业领军型人才钱雪明博士于2012年创立，专注于创新生物药发现、临床研究和商业化开发，重点关注癌症和其他疾病的抗体治疗领域。迈博斯生物在苏州生物医药产业园拥有占地5000平方米的药物发现、临床和转化研究中心，公司自主研发的免疫耐受屏障突破技术平台能发现具有更多表位的抗体，并根据此技术建立了多个抗体发现及共同开发的合作关系，以研发更多能拯救生命且经济有效的抗体疗法。